Diagnosis and treatment of diffuse large B-cell lymphoma

Diagnosis and treatment of diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituxi...

Full description

Bibliographic Details
Main Authors:	Ulrich J. M. Mey, Felicitas Hitz, Andreas Lohri, Stefanie Pederiva, Christian Taverna, Alexander Tzankov, Oliver Meier, Karen Yeow, Christoph Renner
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2012-01-01
Series:	Swiss Medical Weekly
Subjects:	chemotherapy DLBCL first-line treatment follow-up maintenance treatment relapsed/refractory disease
Online Access:	https://www.smw.ch/index.php/smw/article/view/1427

Similar Items

Diagnosis and treatment of follicular lymphoma
by: F Hitz, et al.
Published: (2011-08-01)

Diagnosis and treatment of follicular lymphoma: an update
by: Mario Bargetzi, et al.
Published: (2018-07-01)

Diagnosis and treatment of mantle cell lymphoma
by: Felicitas Hitz, et al.
Published: (2013-11-01)

Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy
by: Helmneh M. Sineshaw, et al.
Published: (2024-04-01)

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
by: Rita Assi, et al.
Published: (2021-03-01)

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
by: Shalini Balendran, et al.
Published: (2023-10-01)

Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis
by: Ping Yang, et al.
Published: (2023-06-01)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
by: Xuzhao Zhang, et al.
Published: (2022-05-01)

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
by: Matthias A. Fante, et al.
Published: (2023-05-01)

Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma
by: Jili Deng, et al.
Published: (2022-12-01)

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
by: Maria Cristina Pirosa, et al.
Published: (2024-12-01)

The Evaluation and Follow-up Patients with First Seizure
by: Hakan SALMAN, et al.
Published: (2022-04-01)

Supplementum 216: Diagnosis and treatment of marginal zone lymphoma
by: Sergio Cogliatti, et al.
Published: (2016-08-01)

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
by: Chenggong Li, et al.
Published: (2023-01-01)

The potential value of ultrasound in predicting local refractory/relapse events in primary thyroid lymphoma patients
by: Jiang Ji, et al.
Published: (2024-03-01)

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
by: Thomas Daikeler, et al.
Published: (2015-01-01)

The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS
by: Ji-Wei Li, et al.
Published: (2024-01-01)

A Questionnaire-Based Survey on the Long-Term Management of Canine Leishmaniosis by Veterinary Practitioners
by: Maria A. Pereira, et al.
Published: (2022-03-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results
by: Natalia S. Tsaplina, et al.
Published: (2023-05-01)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
by: Anna Nydegger, et al.
Published: (2021-12-01)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
by: Aurélie Cabannes‐Hamy, et al.
Published: (2018-03-01)

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
by: Ramy Rahmé, et al.
Published: (2024-01-01)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01)

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China
by: Jiaxin Liu, et al.
Published: (2023-10-01)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
by: Javier de la Rubia, et al.
Published: (2023-05-01)

Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas
by: David R. Minor, et al.
Published: (2023-12-01)

Successful Treatment of Gastrosplenic Fistula Arising from Diffuse Large B-Cell Lymphoma with Chemotherapy: Two Case Reports
by: Makoto Saito, et al.
Published: (2019-05-01)

Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study)
by: Chaoyu Wang, et al.
Published: (2023-03-01)

Follow-up assessment of visceral leishmaniasis treated patients and the impact of COVID-19 on control services in Nepal
by: Anand Ballabh Joshi, et al.
Published: (2023-10-01)

FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center
by: Şebnem Yılmaz Bengoa, et al.
Published: (2017-02-01)

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
by: Panagiotis Samaras, et al.
Published: (2015-02-01)

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trialResearch in context
by: Bushu Xu, et al.
Published: (2023-10-01)

Anthelmintic treatment follow up in a rural community in Camamu, Bahia, Brazil
by: MARINA M.B. FARIAS, et al.
Published: (2023-10-01)

Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP
by: Mohammad Ma'koseh, et al.
Published: (2023-12-01)

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
by: Samantha Pozzi, et al.
Published: (2021-10-01)

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
by: Alejandro Martín García-Sancho, et al.
Published: (2023-12-01)

Neurosurgical Management of Central Nervous System Lymphoma: Lessons Learnt from a Neuro-Oncology Multidisciplinary Team Approach
by: Maria Alexandra Velicu, et al.
Published: (2023-04-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Multiply Relapsed Secondary CNS Non-Germinal Center Diffuse Large B-Cell Lymphoma Successfully Treated with CNS-Centric Therapy
by: Fournier LL, et al.
Published: (2023-08-01)